Carisma’s Positive CT-0508 Data and OrthoCellix Merger Fuel 167% Stock Rally

Introduction

Carisma Therapeutics Inc (NASDAQ: CARM) is a clinical-stage biopharmaceutical company headquartered in Philadelphia, Pennsylvania. Founded in 2016, Carisma utilizes a proprietary platform to engineer macrophages and monocytes—key players in the innate and adaptive immune response—into chimeric antigen receptor (CAR) therapies. Its pipeline includes therapies targeting oncology, fibrosis, and autoimmune disorders, with a focus on solid tumors that may not respond to existing cell therapies.

Corporate Structure

• Headquarters: Philadelphia, PA
• Founded: 2016
• Employees: 51–200 (LinkedIn)
• Leadership:
  • Steven Kelly, President & CEO (joined February 2018; MBA, Cornell University)
  • Michael Klichinsky, PharmD, PhD, Co-Founder & Chief Scientific Officer

Biopharmaceuticals by little plant

Developments and News

• In June 2025, Carisma published Phase 1 results for CT-0508 in Nature Medicine, indicating anti-tumor activity, tumor microenvironment remodeling, and a favorable safety profile in patients with metastatic HER2+ solid tumors.
• Carisma plans to initiate a Phase 1 trial for CT-1119, an ex vivo gene-modified autologous CAR-Monocyte therapy targeting mesothelin-positive solid tumors, for ovarian and pancreatic cancers in Q4 2025.
• The company is collaborating with Moderna Therapeutics on:
  • An in vivo anti-glypican 3 (GPC3) CAR-Macrophage program for the treatment of hepatocellular carcinoma
  • Two in vivo CAR-Macrophage research programs targeting autoimmune diseases
• In August 2025, Carisma entered into a definitive merger agreement with OrthoCellix, a subsidiary of Ocugen (NASDAQ: OCGN), to create a combined entity listed on Nasdaq that will focus on regenerative cell therapies for orthopedic diseases.

Financial and Strategic Analysis

As of September 2, 2025, Carisma’s shares closed at $0.5756 on the NASDAQ, reflecting a year-to-date increase of 167.72%. The trading volume for the day was 45,528,205 shares. Key financial metrics for the trailing twelve months include:

• Revenue: $10.77 million
• Net loss: $49.38 million
• Price/Sales: 0.83
• Total cash: $2 million
• Levered free cash flow: –$21.34 million

The company's cash position supports its ongoing clinical programs. Strategic partnerships, particularly with Moderna, and a diverse pipeline across oncology, fibrosis, and autoimmunity are intended to mitigate risks associated with development. The merger with OrthoCellix also aims to expand Carisma’s market presence in orthopedic regenerative therapies.

Market Position and Industry Context

Carisma functions within the cell-therapy segment of the biotechnology sector, characterized by rapid innovation and substantial development costs. Unlike CAR-T therapies, which primarily target hematologic malignancies, CAR-Macrophages are designed to address solid tumors and the tumor microenvironment. Collaborations with established firms such as Moderna provide Carisma access to lipid nanoparticle and mRNA delivery technologies. Upcoming clinical results in ovarian, pancreatic, and liver cancers will be significant in determining the company’s competitive position relative to larger pharmaceutical companies and other emerging cell-therapy firms.

tl;dr

– CT-0508 Phase 1 results were published in Nature Medicine in June 2025, demonstrating anti-tumor activity and safety in HER2+ solid tumors.
– CT-1119 is expected to begin its Phase 1 trial in Q4 2025 for ovarian and pancreatic cancers.
– Carisma shares were priced at $0.5756 on September 2, 2025, reflecting a 167.72% increase year-to-date, with a market capitalization near $9 million.
– The August 2025 merger agreement with OrthoCellix aims to establish a Nasdaq-listed regenerative cell therapy company focused on orthopedic applications.